{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["157(11)"],"submitter":["Beierlein M"],"funding":["Novartis Deutschland GmbH"],"pubmed_abstract":["Patients with hormone receptor-positive (HRpos), HER2-negative (HER2neg) breast cancer (BC) benefit less from neoadjuvant chemotherapy (NACT) than patients with triple-negative and HER2-positive BC. In this retrospective analysis of the phase IV PreFace clinical trial (NCT01908556), where postmenopausal HRpos BC patients (n = 3297) were treated with 5-year upfront adjuvant letrozole therapy, we evaluated the prognosis of patients treated with adjuvant versus neoadjuvant chemotherapy in HRpos/HER2neg early-stage BC. HRpos/HER2neg patients with information on (neo)adjuvant chemotherapy (n = 2895) were retrospectively selected from all patients enrolled in the PreFace trial. Invasive disease-free survival (iDFS) and overall survival (OS) were compared between patient groups that were treated "],"journal":["International journal of cancer"],"pagination":["2363-2373"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12496005"],"repository":["biostudies-literature"],"pubmed_title":["Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial."],"pmcid":["PMC12496005"],"pubmed_authors":["Sutterlin MW","Marme F","Bohm S","Muller V","Bayer CM","Thomssen C","Huebner H","Fehm TN","Wolf C","Uhrig S","Hofmann NM","Luck HJ","Jackisch C","Theuser AK","Kellner S","Brucker SY","Kolberg HC","Brucker C","Almstedt K","Dall P","Schneeweiss A","Hanf V","Aktas B","Kummel S","Wallwiener D","Nabieva N","Uleer C","Maass N","Ruebner M","Rack B","Rody A","Fasching PA","Beierlein M","Hack CC","Kalder M","Juhasz-Boss I","Belleville E","Haberle L","Janni W","Gass P","Hein A","Schmatloch S","Rauh C","Goossens C"],"additional_accession":[]},"is_claimable":false,"name":"Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial.","description":"Patients with hormone receptor-positive (HRpos), HER2-negative (HER2neg) breast cancer (BC) benefit less from neoadjuvant chemotherapy (NACT) than patients with triple-negative and HER2-positive BC. In this retrospective analysis of the phase IV PreFace clinical trial (NCT01908556), where postmenopausal HRpos BC patients (n = 3297) were treated with 5-year upfront adjuvant letrozole therapy, we evaluated the prognosis of patients treated with adjuvant versus neoadjuvant chemotherapy in HRpos/HER2neg early-stage BC. HRpos/HER2neg patients with information on (neo)adjuvant chemotherapy (n = 2895) were retrospectively selected from all patients enrolled in the PreFace trial. Invasive disease-free survival (iDFS) and overall survival (OS) were compared between patient groups that were treated ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-04T04:20:21.031Z","creation":"2026-05-04T03:14:12.594Z"},"accession":"S-EPMC12496005","cross_references":{"pubmed":["40641449"],"doi":["10.1002/ijc.70037"]}}